Tarlatamab demonstrates durable activity in previously treated SCLC
23 Apr 2025
byDr. Herbert Loong, Department of Clinical Oncology, Chinese University of Hong Kong; Prof. Jürgen Wolf, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
In phase I and II trials, tarlatamab demonstrated promising anticancer activity and a manageable safety profile in heavily pretreated small-cell lung cancer (SCLC) patients – a population with limited treatment options. At an industry-sponsored symposium held during the Immuno-Oncology Hong Kong (IOHK) 2024 conference, Professor Jürgen Wolf of the Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany, presented long-term follow-up data demonstrating tarlatamab’s sustained efficacy and safety, and Dr Herbert Loong of the Department of Clinical Oncology, the Chinese University of Hong Kong, shared local trial participants’ experience with tarlatamab.
